Literature DB >> 30776522

Adverse Events in Oral Immunotherapy for the Desensitization of Cow's Milk Allergy in Children: A Randomized Controlled Trial.

Sarah De Schryver1, Bruce Mazer2, Ann E Clarke3, Yvan St Pierre4, Duncan Lejtenyi2, Alexandra Langlois2, Bahar Torabi2, Wei W Zhao2, Edmond S Chan5, Ingrid Baerg5, Moshe Ben-Shoshan2.   

Abstract

BACKGROUND: This study focuses on the side effects of cow's milk oral immunotherapy (CM-OIT) using consensus definitions of food-induced anaphylaxis.
OBJECTIVE: To evaluate the risk of allergic reactions (ARs) and to identify risk factors associated with higher risk of anaphylactic ARs (AARs) during CM-OIT in children.
METHODS: Clinical charts of children receiving CM-OIT were carefully reviewed. ARs were defined as single-organ ARs, and AARs were defined as involvement of 2 organ systems and/or hypotension in response to CM protein. Descriptive statistics were used to represent demographics, occurrence, reaction characteristics, and comorbidities. Poisson analysis was performed to evaluate risk factors associated with AARs.
RESULTS: Among 41 children undergoing CM-OIT, 11 discontinued the treatment (N = 26.8%). The mean age at challenge was 12.1 years (standard deviation [SD], 3.6) and half were male (56.1%). The mean number of AARs per patient was 6.0 (SD, 3.5) versus a mean of 17.4 (SD, 11.9) non-AARs per patient. Among withdrawals from OIT, the mean number of AARs per patient was 8.3 versus 5.1 in nonwithdrawals. AARs were more frequent in children with higher specific IgE (sIgE) for α-lactalbumine and casein at baseline (1.11 [95% confidence interval (CI): 1.01, 1.22] and 1.01 [1.0, 1.03], respectively). Children with resolved eczema and higher sIgE for β-lactoglobuline at baseline (0.13 [95% CI: 0.04, 0.46] and 0.96 [95% CI: 0.94, 0.99], respectively) were less likely to develop AARs.
CONCLUSIONS: Although the majority of ARs during OIT are nonanaphylactic, AARs occur frequently. Children with higher sIgE for α-lactalbumine and casein at baseline seem to be at higher risk for AARs during OIT.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anaphylaxis; Children; Cow's milk allergy; Oral immunotherapy; Safety

Year:  2019        PMID: 30776522     DOI: 10.1016/j.jaip.2019.02.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  12 in total

1.  Risk factors for discontinuing oral immunotherapy in children with persistent cow milk allergy.

Authors:  Elisa Benelli; Andrea Trombetta; Laura Badina; Stefanny Andrade; Giulia Zamagni; Antonio Prisco; Eugenio Traini; Egidio Barbi; Irene Berti
Journal:  Immun Inflamm Dis       Date:  2022-07

2.  Anaphylaxis to goat/sheep's milk in a 4-year-old boy tolerant to cow's milk.

Authors:  Pasquale Mulé; Sofianne Gabrielli; Julia Upton; Abrams Em; Moshe Ben-Shoshan
Journal:  BMJ Case Rep       Date:  2020-01-08

Review 3.  Molecular Approaches for Diagnosis, Therapy and Prevention of Cow´s Milk Allergy.

Authors:  Birgit Linhart; Raphaela Freidl; Olga Elisyutina; Musa Khaitov; Alexander Karaulov; Rudolf Valenta
Journal:  Nutrients       Date:  2019-06-29       Impact factor: 5.717

Review 4.  Oral Immunotherapy (OIT): A Personalized Medicine.

Authors:  Francesca Mori; Simona Barni; Giulia Liccioli; Elio Novembre
Journal:  Medicina (Kaunas)       Date:  2019-10-13       Impact factor: 2.430

Review 5.  Cow's Milk Protein Allergy as a Model of Food Allergies.

Authors:  Arianna Giannetti; Gaia Toschi Vespasiani; Giampaolo Ricci; Angela Miniaci; Emanuela di Palmo; Andrea Pession
Journal:  Nutrients       Date:  2021-04-30       Impact factor: 5.717

6.  Life-threatening anaphylaxis in children with cow's milk allergy during oral immunotherapy and after treatment failure.

Authors:  Laura Badina; Francesca Burlo; Beatrice Belluzzi; Sara Babich; Irene Berti; Egidio Barbi
Journal:  Immun Inflamm Dis       Date:  2022-04

7.  Successful Milk Oral Immunotherapy Promotes Generation of Casein-Specific CD137+ FOXP3+ Regulatory T Cells Detectable in Peripheral Blood.

Authors:  Yi Zhang; Lei Li; Geneviève Genest; Wei Zhao; Dan Ke; Sabrina Bartolucci; Nils Pavey; Tho-Alfakar Al-Aubodah; Duncan Lejtenyi; Bahar Torabi; Moshe Ben-Shoshan; Bruce Mazer; Ciriaco A Piccirillo
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

8.  Skin prick test in milk allergic patients undergoing oral immunotherapy: Does the milk form used for skin tests matter?

Authors:  Esraa Bukhari; Sofianne Gabrielli; Christine McCusker; Julia Upton; Eyal Grunebaum; Edmond S Chan; Liane Beaudette; Alexandra Langlois; Bahar Torabi; Duncan Lejtenyi; Ann E Clarke; Danbing Ke; Bruce David Mazer; Moshe Ben-Shoshan
Journal:  Front Allergy       Date:  2022-08-08

Review 9.  CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy.

Authors:  P Bégin; E S Chan; H Kim; M Wagner; M S Cellier; C Favron-Godbout; E M Abrams; M Ben-Shoshan; S B Cameron; S Carr; D Fischer; A Haynes; S Kapur; M N Primeau; J Upton; T K Vander Leek; M M Goetghebeur
Journal:  Allergy Asthma Clin Immunol       Date:  2020-03-18       Impact factor: 3.406

10.  Home epinephrine-treated reactions in food allergy oral immunotherapy: Lessons from the coronavirus disease 2019 lockdown.

Authors:  Liat Nachshon; Michael R Goldberg; Michael B Levy; Naama Epstein-Rigbi; Yael Koren; Arnon Elizur
Journal:  Ann Allergy Asthma Immunol       Date:  2021-05-16       Impact factor: 6.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.